Table 2.
Baseline | 6 months | 12 months | |||||||
---|---|---|---|---|---|---|---|---|---|
HAQ | SF‐36 PCS | SF‐36 MCS | HAQ | SF‐36 PCS | SF‐36 MCS | HAQ | SF‐36 PCS | SF‐36 MCS | |
Baseline GAS3‐step‐a | 0.50 | −0.57 | −0.31 | 0.38 | −0.24 | −0.34 | |||
Baseline GAS1‐step‐a | 0.50 | −0.57 | −0.31 | ||||||
6 months GAS3‐step‐a | 0.35 | −0.36 | −0.31 | 0.43 | −0.48 | −0.33 | |||
6 months GAS1‐step‐a | 0.34 | −0.36 | −0.31 | 0.41 | −0.47 | −0.31 | |||
12 months GAS3‐step‐a | 0.38 | −0.34 | −0.24 | 0.40 | −0.41 | −0.25 | 0.55 | −0.60 | −0.32 |
12 months GAS1‐step‐a | 0.38 | −0.36 | −0.24 | 0.39 | −0.40 | −0.26 | 0.53 | −0.60 | −0.33 |
Baseline GAS3‐step‐b | 0.50 | −0.57 | −0.31 | ||||||
Baseline GAS1‐step‐b | 0.50 | −0.57 | −0.30 | ||||||
6 months GAS3‐step‐b | 0.35 | −0.36 | −0.31 | 0.42 | −0.48 | −0.33 | |||
6 months GAS1‐step‐b | 0.35 | −0.36 | −0.30 | 0.41 | −0.46 | −0.32 | |||
12 months GAS3‐step‐b | 0.38 | −0.34 | −0.24 | 0.41 | −0.40 | −0.25 | 0.54 | −0.59 | −0.33 |
12 months GAS1‐step‐b | 0.39 | −0.37 | −0.23 | 0.39 | −0.40 | −0.27 | 0.53 | −0.59 | −0.33 |
Baseline GAS3‐step‐c | 0.45 | −0.51 | −0.29 | ||||||
Baseline GAS1‐step‐c | 0.44 | −0.50 | −0.28 | ||||||
6 months GAS3‐step‐c | 0.30 | −0.30 | −0.27 | 0.38 | −0.43 | −0.32 | |||
6 months GAS1‐step‐c | 0.29 | −0.30 | −0.27 | 0.37 | −0.41 | −0.31 | |||
12 months GAS3‐step‐c | 0.34 | −0.30 | −0.21 | 0.36 | −0.36 | −0.20 | 0.50 | −0.53 | −0.30 |
12 months GAS1‐step‐c | 0.34 | −0.30 | −0.20 | 0.35 | −0.35 | −0.23 | 0.49 | −0.53 | −0.30 |
All Spearman's rho coefficient P values < 0.001. HAQ = Health Assessment Questionnaire; SF‐36 = Short Form 36 health survey; PCS = physical component summary; MCS = mental component summary; GAS = Gout Activity Score.